This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Founded in 1846 and based in Ewing, NJ , Church & Dwight Co., Inc. develops, manufactures and markets a broad range of household, personal care and specialty products. It is the leading U.S. producer of sodium bicarbonate, popularly known as baking soda, a natural product that cleans, deodorized, leavens and buffers. The company operates in six countries (Canada, Mexico, U.K., France, Australia and Brazil) and exports to over 90 other countries. Approximately 17% of the company’s net sales came from outside the U.S. in 2019. The company has 12 key brands, including ARM & HAMMER, Trojan, OxiClean, Spinbrush, First Response, Nair, Orajel, Xtra, L’IL CRITTERS and VITAFUSION, Waterpik, FLAWLESS and Batiste. The company’s ARM & HAMMER brand is one of the nation’s most trusted trademarks for a broad range of consumer and specialty products and its products are sold under ARM & HAMMER liquid and powder laundry detergent, ARM & HAMMER cat litter, ARM & HAMMER dental care and ARM & HAMMER baking soda. Markedly, eleven out twelve power brands were acquired by the company and added to its portfolio since 2001.
Nu Skin (NUS) Gears Up for Q2 Earnings: What's in Store?
by Zacks Equity Research
Nu Skin's (NUS) second-quarter 2023 performance will likely reflect macroeconomic challenges like rising global inflation. Also, unfavorable currency rates are a concern.
Albertsons (ACI) Q1 Earnings Beat Estimates, Sales Rise Y/Y
by Zacks Equity Research
Albertsons' (ACI) fiscal first-quarter results showcase the robustness of its business and the success of the Customers for Life transformation strategy amid increasing economic challenges.
Clorox (CLX) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Clorox (CLX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why Procter & Gamble (PG) is Poised for Q4 Earnings Beat
by Zacks Equity Research
Procter & Gamble's (PG) unwavering commitment to leverage its brand strength and adopt effective strategies has been bolstering its organic sales and market position.
Will Church & Dwight (CHD) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Church & Dwight (CHD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Colgate (CL) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Colgate's (CL) second-quarter 2023 sales are likely to have benefited from strong demand for its products, innovation, brand strength and a focus on premiumization. Rising costs and expenses might have hurt its margins.
Factors Likely to Decide Newell's (NWL) Fate in Q2 Earnings
by Zacks Equity Research
The ongoing tough environment, reduced inventory and inflationary pressures are likely to have dented Newell's (NWL) Q2 earnings despite productivity and efficiency initiatives.
Factors to Note Ahead of FEMSA's (FMX) Upcoming Q2 Earnings
by Zacks Equity Research
FEMSA's (FMX) Q2 results are expected to reflect gains from continued strength in OXXO Mexico and OXXO Gas, expansion into newer businesses, and digital initiatives amid cost woes.
Will Soft Shipment Trend Mar Boston Beer's (SAM) Q2 Earnings?
by Zacks Equity Research
Boston Beer's (SAM) Q2 results are expected to reflect the continued impacts of declining shipments and depletions, and challenges in the hard seltzer category.
Mondelez (MDLZ) Gears Up for Q2 Earnings: What's in Store?
by Zacks Equity Research
Mondelez's (MDLZ) second-quarter 2023 performance is likely to gain from effective pricing actions and prudent buyouts. Strength in the company's snacking category is an upside.
Is a Beat in Store for Church & Dwight (CHD) in Q2 Earnings?
by Zacks Equity Research
Church & Dwight's (CHD) second-quarter results are likely to reflect gains from pricing, innovation and demand amid elevated costs.
The Hershey Company (HSY) Queues for Q2 Earnings: What Awaits?
by Zacks Equity Research
The Hershey Company's (HSY) second-quarter results are likely to reflect gains from pricing and innovation. Prudent buyouts have also been a driver.
Church & Dwight (CHD) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Church & Dwight (CHD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pilgrim's Pride (PPC) Queues for Q2 Earnings: What's in Store?
by Zacks Equity Research
Pilgrim's Pride's (PPC) second-quarter results are likely to reflect the impacts of cost inflation, while customer-centric initiatives and solid foodservice demand bode well.
Is a Beat in Store for Kimberly-Clark (KMB) in Q2 Earnings?
by Zacks Equity Research
Kimberly-Clark's (KMB) second-quarter results are likely to reflect gains from revenue management efforts and strategic growth pillars amid cost inflation.
Clorox (CLX) Gains From Digital Initiatives & Pricing Power
by Zacks Equity Research
Clorox's (CLX) IGNITE strategy serves as a catalyst for driving innovation, enhancing operational efficiency and bolstering international growth.
Procter & Gamble (PG) Widens Spectrum on Value Creation
by Zacks Equity Research
Procter & Gamble (PG) advances the execution of the integrated strategies -- Supply Chain initiatives and digital penetration to strengthen the organization.
3 Stocks to Buy for Decreased Volatility
by Derek Lewis
With CPI looming, investors may want to visit low-beta stocks as a shield against volatility. As we all know by now, CPI days have become quite a market-moving event.
Church & Dwight (CHD) Shares Up 21.9% YTD: What's Driving It?
by Zacks Equity Research
Church & Dwight (CHD) gains from its strength across end markets, acquired assets, its solid online channel and shareholder-friendly policies.
Beat the Market the Zacks Way: Vertiv, Costco, Sonnet BioTherapeutics in Focus
by Zacks Equity Research
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
McCormick (MKC) Gears Up for Q2 Earnings: Things to Note
by Zacks Equity Research
McCormick's (MKC) second-quarter results are likely to reflect gains from the Comprehensive Continuous Improvement program amid cost inflation.
General Mills (GIS) Gears Up for Q4 Earnings: Things to Note
by Zacks Equity Research
General Mills' (GIS) fourth-quarter fiscal 2023 results are likely to reflect gains from the Accelerate strategy amid cost inflation.
Church & Dwight (CHD) Rides on Business Strength Amid Risks
by Zacks Equity Research
Church & Dwight (CHD) is set to benefit from solid product demand, new product launches and buyouts. However, escalating costs and expenses remain concerns.
Implied Volatility Surging for Church & Dwight (CHD) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Church & Dwight (CHD) stock based on the movements in the options market lately.
Campbell Soup (CPB) to Report Q3 Earnings: Things to Note
by Zacks Equity Research
Campbell Soup's (CPB) third-quarter results are likely to reflect gains from pricing and Snacks business strength amid cost woes.